BioNexus Gene Lab Corporation (BGLC)

OTCMKTS: BGLC · Delayed Price · USD
-0.001 (-0.47%)
May 31, 2023, 10:29 AM EDT - Market open
Market Cap 49.98M
Revenue (ttm) 10.28M
Net Income (ttm) -442,098
Shares Out 173.72M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,762
Open 0.210
Previous Close 0.297
Day's Range 0.200 - 0.296
52-Week Range 0.160 - 1.260
Beta 0.75
Analysts n/a
Price Target n/a
Earnings Date n/a

About BGLC

BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additi... [Read more]

Sector Healthcare
Founded 2017
Employees 27
Stock Exchange OTCMKTS
Ticker Symbol BGLC
Full Company Profile

Financial Performance

Financial Statements


There is no news available yet.